BNTX
BioNTech SE NASDAQ$99.35
After hrs
$95.19
-0.32%
Mkt Cap $25.0B
52w Low $79.52
44.6% of range
52w High $124.00
50d MA $97.65
200d MA $102.61
P/E (TTM)
-21.6x
EV/EBITDA
-47.5x
P/B
1.2x
Debt/Equity
0.0x
ROE
—
P/FCF
72.6x
RSI (14)
—
ATR (14)
—
Beta
1.59
50d MA
$97.65
200d MA
$102.61
Avg Volume
1.1M
About
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | BMO | -0.22 | -0.38 | -72.7% | 83.89 | +2.8% | +8.3% | +8.3% | +7.4% | +8.7% | +7.9% | — |
| Nov 3, 2025 | BMO | -1.12 | -0.14 | +87.5% | 103.96 | +0.4% | +0.8% | +0.8% | -0.5% | -0.6% | -0.8% | — |
| Aug 4, 2025 | BMO | -2.69 | -1.82 | +32.3% | 110.03 | +1.0% | +0.9% | +0.9% | +1.2% | +1.2% | +1.5% | — |
| May 5, 2025 | BMO | -2.48 | -1.82 | +26.5% | 101.10 | -0.3% | -6.3% | -6.3% | -8.2% | -6.3% | -8.2% | — |
| Mar 10, 2025 | BMO | 0.46 | 1.15 | +148.7% | 105.35 | -1.7% | -6.6% | -6.6% | -4.8% | -7.5% | -5.6% | — |
| Nov 4, 2024 | BMO | -1.74 | 0.89 | +151.1% | 108.97 | -0.1% | +1.8% | +1.8% | -2.1% | -1.0% | +1.5% | — |
| Aug 5, 2024 | BMO | -2.19 | -3.62 | -65.2% | 78.36 | +0.3% | +1.5% | +1.5% | +1.1% | +2.8% | +3.1% | — |
| May 6, 2024 | BMO | -1.34 | -1.42 | -5.9% | 93.35 | -0.5% | -2.6% | -2.6% | -3.4% | -1.4% | -1.8% | — |
| Mar 20, 2024 | BMO | 2.62 | 2.05 | -21.8% | 90.00 | -0.5% | +2.2% | +2.2% | +2.0% | +3.3% | +1.9% | — |
| Nov 6, 2023 | BMO | -0.62 | 0.73 | +217.0% | 99.71 | -0.4% | +2.7% | +2.7% | -0.1% | -0.4% | -0.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $105.46 | $105.59 | +0.1% | -3.2% | -3.2% | -3.7% | -1.9% | -7.5% |
| Apr 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $91.98 | $92.75 | +0.8% | +3.8% | +5.1% | +7.0% | +8.1% | +11.0% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $85.25 | $86.29 | +1.2% | +4.3% | +4.9% | +7.0% | +7.1% | +5.1% |
| Mar 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $83.89 | $86.28 | +2.8% | +8.3% | +7.4% | +8.7% | +7.9% | +13.1% |
| Mar 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $83.89 | $86.28 | +2.8% | +8.3% | +7.4% | +8.7% | +7.9% | +13.1% |
| Mar 11 | BMO Capital | Maintains | Outperform → Outperform | — | $83.89 | $86.28 | +2.8% | +8.3% | +7.4% | +8.7% | +7.9% | +13.1% |
| Mar 11 | TD Cowen | Maintains | Hold → Hold | — | $83.89 | $86.28 | +2.8% | +8.3% | +7.4% | +8.7% | +7.9% | +13.1% |
| Mar 11 | Citigroup | Maintains | Buy → Buy | — | $83.89 | $86.28 | +2.8% | +8.3% | +7.4% | +8.7% | +7.9% | +13.1% |
| Mar 10 | Jefferies | Maintains | Buy → Buy | — | $102.16 | $82.81 | -18.9% | -17.9% | -11.1% | -11.8% | -10.7% | -11.4% |
| Jan 16 | Goldman Sachs | Upgrade | Neutral → Buy | — | $106.07 | $109.24 | +3.0% | +2.8% | -0.5% | +11.2% | +11.7% | +9.3% |
Data updated apr 26, 2026 9:56am
· Source: massive.com